NCT01415544

Brief Summary

The purpose of the study is to prospectively evaluate a noninvasive, near-infrared based method for measuring glucose concentration relative to invasive blood reference measurements. The initial phase of the study will be focused on procurement of the data needed to develop a robust, accurate calibration. The second phase will be focused on performance evaluation of the system.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2011

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2011

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

August 9, 2011

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 12, 2011

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2012

Completed
Last Updated

February 27, 2012

Status Verified

February 1, 2012

Enrollment Period

8 months

First QC Date

August 9, 2011

Last Update Submit

February 23, 2012

Conditions

Keywords

Diabetes

Outcome Measures

Primary Outcomes (1)

  • Calibrate near-infrared spectroscopy-based glucose meter

    The collection of capillary blood glucose and noninvasive data will allow the calibration of the noninvasive systems and subsequently evaluate performance via a validation study. The paired NIR spectrum and blood reference data acquired during calibration will be processed using multivariate regression techniques to create a calibration model. Results will be compared using a Clark error grid.

    1 year

Secondary Outcomes (1)

  • Compare Noninvasive to invasive techniques

    1 year

Study Arms (4)

Type 2 Diabetes

Those previously diagnosed with type 2 diabetes

Type 1 Diabetes

Those previously diagnosed with type 1 diabetes

Gestational Diabetes

Those that are currently diagnosed with gestational diabetes

Healthy Human Volunteers

Those that have not been diagnosed with any type of diabetes

Eligibility Criteria

Age20 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

The Human Subject population consists of female subjects between the ages of 20 and 50. Subjects must have been diagnosed with either Type I, Type II, or Gestational diabetes and may utilize healthy individuals for the validation phase. Up to 100 subjects may be recruited to participate in this study. Subjects will be recruited from the community and will be selected to ensure a representative sample of the projected intended use population. Efforts will also be made to ensure a broad and even distribution of ages (between 20 and 50 years old) and ethnicities.

You may qualify if:

  • Female at least 20 years of age but not older than 50 years of age
  • Female with Type I or Gestational diabetes based on ADA criteria
  • Female with Type II diabetes and A1c of greater than 7.0 as measured on a Bayer A1C Now meter
  • May include female healthy volunteers.

You may not qualify if:

  • Subject requires hemo-dialysis
  • Severe heart disease as evidenced by peripheral edema
  • Liver disease as evidenced by jaundice
  • Active alcohol or drug abuse
  • Body Mass Index (BMI) \> 35 kg/m2
  • Hand size too large to fit in the optical measurement instrumentation
  • Middle finger width of less than 5 mm
  • Skin damage at optical sampling site on hand
  • Currently taking prednisone or other systemic steroids
  • Tattoo at the optical sampling site

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lovelace Scientific Resources

Albuquerque, New Mexico, 87106, United States

Location

Biospecimen

Retention: NONE RETAINED

capillary glucose measurements

MeSH Terms

Conditions

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes, GestationalDiabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Walter Forman, MD

    Lovelace Scientific Resources

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 9, 2011

First Posted

August 12, 2011

Study Start

June 1, 2011

Primary Completion

February 1, 2012

Study Completion

February 1, 2012

Last Updated

February 27, 2012

Record last verified: 2012-02

Locations